Jinglin Shi

Jinglin Shi

Auto-generated profile, based on publicly available information

Jinglin Shi

Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
GZGuoxi Zhang
Guoxi Zhang
JZJunrong Zou
Junrong Zou
JSJinglin Shi
Jinglin Shi
BQBiao Qian
Biao Qian
KQKaiyang Qiu
Kaiyang Qiu
XZXiaofeng Zou Xiaofeng Zou
Xiaofeng Zou Xiaofeng Zou

9 November 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
GZGuoxi Zhang
Guoxi Zhang
JZJunrong Zou
Junrong Zou
JSJinglin Shi
Jinglin Shi
BQBiao Qian
Biao Qian
KQKaiyang Qiu
Kaiyang Qiu
XZXiaofeng Zou Xiaofeng Zou
Xiaofeng Zou Xiaofeng Zou
Small ubiquitin-related modifier (SUMO) proteins are involved in the development of tumors. Ubiquitin-like modifier-activating enzyme 2 (UBA2) is an important member of the SUMO modification system; however, its role in clear cell renal cell carcinoma (ccRCC) is unclear. Therefore, we investigated the expression and function of UBA2 in ccRCC. Both mRNA and protein expression levels of UBA2 were found to be higher in ccRCC than in normal renal tissues and significantly related to the tumor size, Fuhrman grade, and tumor stage. UBA2 knockdown inhibited ccRCC cell growth, promoted apoptosis in vitro and in vivo, and decreased the abundance of a p53 mutant, c-Myc, and key enzymes of the SUMO modification system. Meanwhile, overexpression of UBA2 had the opposite effects. Overexpression of the p53 mutant or c-Myc alleviated the effects of UBA2 knockdown on ccRCC cell proliferation and apoptosis. In conclusion, targeting UBA2 may have a therapeutic potential against ccRCC.